MY PICK IS ELN

[skiracer]

I've done very well with it on several swings an never ever thought I would see it this low again. Will be looking for another entry under $14 this Monday. Only wish I hadn't procrastinated Friday when it was $13.10 or so. Thought $14.10 was great on Thursday and it dropped another point before reversing back to $13.67. Could it do another big drop again on Monday to around $12.10. I don't think so but that would be a big surprise to alot of people and these stocks never fail to surprise an amaze me with their actions regardless of what the chart indicates. Over 78 million in volume between Thursday and Friday. This is a fabulous buying opportunity and Webs if you don't sell off everything else to raise some cash to buy it again at this level you will be regretting it come Wed. or Thursday of this coming week.

[Websman]

This is a fabulous buying opportunity and Webs if you don't sell off everything else to raise some cash to buy it again at this level you will be regretting it come Wed. or Thursday of this coming week.

I've already sold everything else off...

I have plenty of cash and will more than likely buy some more. this is a great opportunity.

[kingofthehill]

ok a couple of quick points

1 there will be a FDA panel review for TYSABRI March 7th in MD

2. the day before te panel March 6th the FDA insiders will publish thier written opinion of the drug. very important paper!

3. Jan 31st Elan should tal more about Alzhiemers disease vaccine they are workin on with Wyeth.

4. on or before March 26th the FDA will announce a yea or nay



FDA Advisory Panel on Tysabri Scheduled for March 7th

--------------------------------------------------------------------------------

Here is the link for the agenda:

http://www.fda.gov/oc/advisory/accal...43d030706.html

Since this is a government site the information can be posted here:

Peripheral and Central Nervous System Drugs Advisory Committee
Center Date Time Location
CDER March 7, 2006 8:00 a.m. - 5:00 p.m. Holiday Inn Gaithersburg
The Ballrooms
Two Montgomery Village Ave.
Gaithersburg, MD

Agenda:
The committee will discuss TYSABRI (natalizumab) biologic license application 125104/15; Biogen Idec Inc., for an indication in patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. The committee will discuss the risks (including progressive multifocal leukoencephalopathy) associated with TYSABRI (natalizumab) administration, its efficacy in the treatment of multiple sclerosis relapses and/or disability, its possible return to the marketplace, and its proposed risk management plan(s).

Background material and meeting information will become available no later than one business day before the meeting (Simply scroll down to the appropriate committee heading).

Procedure:
Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 28, 2006. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 28, 2006, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Sohail Mosaddegh at least 7 days in advance of the meeting.

[kingofthehill]

Remember: Orla Hartford is the one with the Phd. and pharma background. A little bit more qualified than the Silvers of this world.

Elan $13.66 BUY FDA Advisory Committee Date
• On March 7th 2006 the Peripheral and Central Nervous System Drugs Advisory
Committee will review TYSABRI (to be held at the Holiday Inn Gaithersburg, Maryland)
and provide a recommendation to the FDA for the re-launch of Tysabri for multiple
sclerosis in the US. The committee will focus on (i) the risks associated with Tysabri
including the PML risk, (ii) the proposed risk management plans, (iii) the efficacy of
Tysabri in the treatment of multiple sclerosis relapses and/or disability and (iv) the
subsequent return of Tysabri to the market. Given the concerns we have previously
raised about Tysabri in combination with AVONEX we also expect this issue to be
focused on by the committee.
• The members on the advisory committee are available on the following link:
http://www.fda.gov/cder/audiences/ac...ralroster1.htm and include
neurologists, a statistician, an epidemiologist and a industry representative. While
overall we would expect this panel to recommend to the FDA the re-launch of Tysabri,
the risk of negative commentary ahead of the panel’s decision could generate negative
sentiment and weak share price performance.
• The re-launch of Tysabri is expected to coincide with the publication of the revised
label, which will highlight the two cases of PML in patients on combination therapy
and the risk of PML should a patient be immunosuppressed, along with further data
from the two-year Phase III clinical studies. We continue to believe that the FDA will
approve the re-launch of Tysabi as a treatment option for MS patients by the end of
March 2006.

Links provided:

http://www2.ncbdirect.com/EquityBook/HTML/ELN.htm

http://www.fda.gov/cder/audiences/acspage/peripheralroster1.htm

[Tormentos]

Hey guys just wanted to chime in that I'm still holding on to this one. I posted back in this thread around June of last year.

I got in on ELN at 6.60. Took a small profit @ 7.50.

Re-entered when it dropped to 6.69 & ended up riding that all the way to the recent peak. Ended up selling @ 16.10.

Well I'm back in again @ 14.05. Hope this goes well in the next couple months for all of us. I just started trading when I graduated from college 2 years ago. I'm still in the stage where I am trying to suck up as much info as possible. This has been one of my best trades so far, thanks for everyone's insight into this stock!

[spikefader]

Hiya Tormentos; why you torment-us so much! lol

Seriously though, congrats on doing so well with it. You were braver than I was smart buying under 10.00. But as a wise trader on MM says, "That's what makes a horse race"! Post more of those great entries dude!

[kingofthehill]

spike any TA calls?

[noshadyldy]

Spike, do you think it's safe (sort of) to say that ELN is done reacting to the Lehman article?

[spikefader]

OK guys......ELN has me worried for my entry ~boo hoo~ If I'm lucky this coming C is not gonna drop far....but I could easy get taken out and will be lookin' fer another entry. For anyone thinkin', but Spike, it's in the C, just hold on; I'll say this: No way I'm takin' a loss on this trade.

I actually SERIOUSLY thinking of bailing on this position, locking in my 12% at the open and stalking the C completion.

Opinions?

[Websman]

I would like to see ELN drop back to the low 13's before the big move up. That way I could buy some more shares cheap.

[skiracer]

Spike, do you think it's safe (sort of) to say that ELN is done reacting to the Lehman article?

Noshadylady,
I didn't catch that Lehman article. What did it say?

[kingofthehill]

huge positive article on Elan tonight, rakes the Lehman Bros. report over the coals....and also www.fool.com was positive on Elan tonight.

http://www.marketocracy.com/media/pdf/researchreport/Elan_012306.pdf

Marketocracy Alert: A Gift from Wall Street
We are issuing this alert because Wall St. gave us another great opportunity to buy shares in Elan Corp. (nyse: ELN).
Lehman Brothers downgraded ELN on Thursday, Jan. 19th to Underweight and sent ELN shares tumbling from
Wednesday’s high of $16.83 to a low of $13.10 on Friday the 20th before closing the week at $13.66. ELN has
rebounded a bit closing at $14.10 on Monday the 23rd but is still a great buying opportunity.
Lehman Brothers joins Citibank, Bank of America, and Merrill Lynch in their negative stance on Elan. It is rare
that you see a situation where so many Wall St. analysts are lined up with such a different opinion from what my
research says. This is the time to back up the truck and load up.

click the link to read all 4 pages

[skiracer]

OK guys......ELN has me worried for my entry ~boo hoo~ If I'm lucky this coming C is not gonna drop far....but I could easy get taken out and will be lookin' fer another entry. For anyone thinkin', but Spike, it's in the C, just hold on; I'll say this: No way I'm takin' a loss on this trade.

I actually SERIOUSLY thinking of bailing on this position, locking in my 12% at the open and stalking the C completion.

Opinions?

Spike,
If the c takes it down to below your entry of $12.62 then I for one will be backing the truck up and loading up for a big position. I bought 2000 shares the other day at $13.85 and have been just sitting and watching it for the last couple of days without a stop since I have been home working in the office all day. I can see the c coming but I can't see it going that low. Personally I'm ready to pull the exit trigger at breakeven ($13.85) if it breaks below that and re-enter on the bottom. There's going to be a rush to get in on the next positive newsbreak.

[noshadyldy]

Eln

I don't hear any mumbling about earnings release on 1/31 before open. Any quibbles about holding so much over earnings?

[noshadyldy]

to SKI

Noshadylady,
I didn't catch that Lehman article. What did it say?

ElanTear Sheet Chart News

Biogen IdecTear Sheet Chart News

Lehman Brothers analyst Richard Silver downgraded Elan (nyse: ELN - news - people ) stock to “underweight” from “equal-weight” citing “overextended” valuation following a meeting with management of Elan’s partner Biogen Idec (nasdaq: BIIB - news - people ) concerning the companies’ multiple sclerosis drug Tysabri.

“In our opinion, at nearly $17 per share, Elan’s valuation more than fully reflects a successful upcoming FDA panel meeting, market re-entry, and future peak sales well in excess of even the most optimistic scenarios,” for Tysabri, the analyst said in a report Thursday.

In Feb. 2005, Biogen and Elan pulled the multiple sclerosis drug from the market.

Silver said that if Tysabri does return to the market, neurologists may be reluctant to broadly prescribe it due to the responsibility of the required strict patient monitoring.

The analyst added patients taking Tysabri face the risk of missing early signs of the rare but life-threatening side effect of progressive multifocal leukoencephalopathy, a brain disorder linked to the drug.